The Federation of European Biochemical Societies (FEBS) was founded in 1964 to bring together the scientific societies of Europe and neighbouring regions and to provide a platform for scientific exchange. Today, FEBS is an organisation of more than 30 000 members across 39 biochemistry and molecular biology societies that promotes excellence in the life sciences in Europe and beyond. To mark the 60 anniversary of FEBS, FEBS Letters celebrated with a writing contest focussed on participants' visions of scientific societies in the year 2084. Here, we present the winning essay, in which Yussuf Ali (Jagiellonian University, Poland) considers a future in which FEBS transcends not only geographical boundaries, but also interdisciplinary, technological and financial boundaries.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1873-3468.15065 | DOI Listing |
Neurol Ther
January 2025
Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, 06510, USA.
Introduction: The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a validated and highly utilized measure for evaluating patients with Friedreich Ataxia. While construct validity of FARS-ADL has been shown for spinocerebellar ataxia (SCA), content validity has not been established.
Methods: Individuals with SCA1 or SCA3 (n = 7) and healthcare professionals (HCPs) with SCA expertise (n = 8) participated in qualitative interviews evaluating the relevance, clarity, and clinical meaningfulness of FARS-ADL for assessment of individuals with SCA.
J Obstet Gynaecol
December 2025
Department of Pediatrics, Obstetrics and Gynecology, Universitat de Valencia, Valencia, Spain.
Background: Research on fertility preservation among women diagnosed with lymphoma is very limited. We aimed to assess the receipt of fertility preservation information and use of fertility preservation among women diagnosed with lymphoma.
Methods: This was a retrospective, single-centre study.
Cell Regen
January 2025
Guangzhou National Laboratory, Guangzhou, 510005, China.
Organoid technology provides a transformative approach to understand human physiology and pathology, offering valuable insights for scientific research and therapeutic development. Human gastric organoids, in particular, have gained significant interest for applications in disease modeling, drug discovery, and studies of tissue regeneration and homeostasis. However, the lack of standardized quality control has limited their extensive clinical applications.
View Article and Find Full Text PDFPhysiol Res
December 2024
Institute of Physiology, Czech Academy of Sciences, 14220 Prague 4, Czech Republic.
The history of the Czech and Slovak experimental cardiology describes a completely unusual curve. The personality of J.E.
View Article and Find Full Text PDFJ Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!